Rybrevant and Lazcluze extend survival in NSCLC
Results from its first-line MARIPOSA trial show that Rybrevant (amivantamab) plus Lazcluze (lazertinib) significantly extended overall survival (OS) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The patients have NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.
Median OS is projected to exceed one year beyond the median of three years observed with osimertinib, but it has not yet been reached.
The new data were presented during a poster session at the 2025 European Lung Cancer Congress (ELCC).
“The survival curve demonstrates that amivantamab plus lazertinib can help patients live longer compared to osimertinib monotherapy, and suggests the benefit keeps growing over time,” said trial investigator Professor Nicolas Girard, Head of Medical Oncology, Institut Curie, and Professor of Thoracic Oncology and Respiratory Medicine at the Paris Saclay University, France.
“We see the gap between the survival curves continue to widen, which is exactly what we want to see in lung cancer treatment to improve outcomes for patients. These results reinforce that we are entering a new era for EGFR-mutated advanced non-small cell lung cancer.”
The MARIPOSA trial
At a median follow-up of 37.8 months, patients treated with first-line amivantamab plus lazertinib had a significantly longer OS compared to those receiving the current standard of care, Osimertinib.
56% of patients treated with amivantamab and lazertinib were alive at three and a half years compared to 44% of patients on osimertinib.
“J&J is committed to getting in front of cancer and redefining the standard of care for people living with lung cancer, and our first line study results bring us closer to making that a reality,” said Dr John Fleming, Country Medical Director UK, Johnson & Johnson Innovative Medicine. “To give people living with lung cancer more time to spend with their loved ones, it’s vital we continue pushing the boundaries of innovation.”
The amivantamab plus lazertinib combination also prolonged multiple secondary endpoints versus osimertinib including intracranial progression-free survival (PFS), duration of response and overall response rate.
Notably, amivantamab plus lazertinib prolonged time to symptomatic progression – the time from treatment randomisation to the onset of new or worsening lung cancer symptoms requiring intervention – by more than 14 months compared to osimertinib.
Diana Spencer, Senior Digital Content Editor, DDW
